Back to today’s briefing

Story perspectives

Ubrogepant Shows Promise in Rapid Migraine Relief

5/13/2025

50 10

Summary

Story summary

The PRODROME study, a pivotal phase 3 trial conducted in the USA from August 2020 to April 2022, explored the effectiveness of ubrogepant in alleviating migraine prodromal symptoms. With 480 participants, the trial aimed for a significant outcome: the relief from moderate to severe headaches within 24 hours of treatment, while also examining cognitive effects and safety.

1 of 1

Story summary

The PRODROME study, a pivotal phase 3 trial conducted in the USA from August 2020 to April 2022, explored the effectiveness of ubrogepant in alleviating migraine prodromal symptoms. With 480 participants, the trial aimed for a significant outcome: the relief from moderate to severe headaches within 24 hours of treatment, while also examining cognitive effects and safety.